Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of A0001 in Patients With the A3243G Mitochondrial DNA Point Mutation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of neuromuscular symptoms due to the A3243G mitochondrial DNA point mutation~* PCR/ATP ratio of \<1.9 following the Cardiac MRS at screening~Exclusion Criteria:~* Any major illness not due to the A3243G mitochondrial DNA point mutation in the past three months or any significant ongoing chronic medical illness, especially significant central nervous neurological disease limiting capacity to carry out the study~* Use of any investigational product within the past 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- A0001 (Type: EXPERIMENTAL): A0001 (0.75 g BID)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).